Cargando…
Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study
Immuno-oncology (IO) combination therapy is utilized as a first-line systemic treatment for advanced renal cell carcinoma. However, evidence supporting the use of cabozantinib after IO combination therapy is lacking. We retrospectively analyzed patients who received second-line cabozantinib after IO...
Autores principales: | Sazuka, Tomokazu, Matsushita, Yuto, Sato, Hiroaki, Osawa, Takahiro, Hinata, Nobuyuki, Hatakeyama, Shingo, Numakura, Kazuyuki, Ueda, Kosuke, Kimura, Takahiro, Takahashi, Masayuki, Tanaka, Hajime, Kawasaki, Yoshihide, Kurahashi, Toshifumi, Kato, Takuma, Fujita, Kazutoshi, Miyake, Makito, Kojima, Takahiro, Kitamura, Hiroshi, Miyake, Hideaki, Ichikawa, Tomohiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667220/ https://www.ncbi.nlm.nih.gov/pubmed/37996622 http://dx.doi.org/10.1038/s41598-023-48087-4 |
Ejemplares similares
-
Cabozantinib inhibits HBV-RNA transcription by decreasing STAT3 binding to the enhancer region of cccDNA
por: Funato, Kazuyoshi, et al.
Publicado: (2023) -
A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data
por: Hinata, Nobuyuki, et al.
Publicado: (2020) -
Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study
por: Miyake, Makito, et al.
Publicado: (2021) -
Subsequent Upper Urinary Tract Carcinoma Related to Worse Survival in Patients Treated with BCG
por: Numakura, Kazuyuki, et al.
Publicado: (2023) -
Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care)
por: Osawa, Takahiro, et al.
Publicado: (2023)